Back to results
US 12,595,516 B2Granted
Neuroendocrine tumors
AssigneeBiotheranostics, Inc.
InventorsCatherine A. Schnabel, Yi Zhang, Mark G. Erlander
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
Claims8
A kit comprising (i) a reverse transcriptase and (ii) probes, primers, or both probes and primers for a gene panel, wherein the gene panel is for classifying a sample as containing pancreatic neuroendocrine tumor cells and wherein the gene panel is a four-gene panel consisting of ELAVL4, CADPS, RGS17, and KCNJ11;
- wherein the probes, primers, or both probes and primers for the four-gene panel consist of:
- one or more probes, primers, or both probes and primers that are complementary to a portion of an ELAVL4 cDNA sequence and are labeled with a fluorescent molecule;
- one or more probes, primers, or both probes and primers that are complementary to a portion of an CADPS cDNA sequence and are labeled with a fluorescent molecule, one or more probes, primers, or both probes and primers that are complementary to a portion of an RGS17 cDNA sequence and are labeled with a fluorescent molecule;
- and one or more fourth probes, primers, or both probes and primers that are complementary to a portion of an KCNJ11 cDNA sequence and are labeled with a fluorescent molecule,
- wherein the kit does not comprise probes, primers, or both probes or primers for genes other than ELAVL4, CADPS, RGS17, and KCNJ11.
2 more elements
Dependencies are inferred from the claim text.